Form 4: Climb Bio CBO Receives 300,000 Stock Options

Climb Bio, Inc.'s Chief Business Officer, Perrin Megan Wilson, was granted 300,000 stock options with an exercise price of $3.81.

Summary

• Perrin Megan Wilson, Chief Business Officer of Climb Bio, Inc. (CLYM), was granted 300,000 stock options.
• The stock options have an exercise price of $3.81 per share.
• The grant date for these options was January 6, 2026.
• The options are scheduled to vest 25% on the first anniversary of the grant date (January 6, 2027).
• The remaining options will vest in 36 equal monthly installments through January 6, 2030.
• Vesting is contingent upon the Reporting Person's continued service to the company.
• The expiration date for these stock options is January 5, 2036.

Sentiment

Score: 6

Explanation: The grant of stock options is a standard executive compensation event, generally viewed as a neutral to slightly positive development as it aligns management incentives with shareholder interests, without indicating immediate operational or financial performance changes.

Positives

• The grant of stock options aligns the Chief Business Officer's long-term financial interests with those of the shareholders.
• This compensation structure serves as an incentive for executive retention and continued service to the company.

Negatives

• The exercise of these options in the future could lead to dilution for existing shareholders.
• The company does not receive immediate cash proceeds from the grant of these options.

Risks

• The vesting of the stock options is subject to the Reporting Person's continued service, meaning unvested options could be forfeited if employment ceases.
• The value of the options is dependent on the future market price of Climb Bio, Inc. common stock exceeding the exercise price of $3.81.

Future Outlook

The vesting schedule for the stock options extends through January 2030, indicating a long-term incentive structure for the Chief Business Officer and a commitment to future performance.

Industry Context

The grant of stock options to a Chief Business Officer is a standard practice in the biotechnology and pharmaceutical industries, serving as a key component of executive compensation packages designed to attract, retain, and motivate key talent by aligning their interests with long-term shareholder value.

Comparison to Industry Standards

• Granting stock options to executives is a common practice in the biotechnology and pharmaceutical industries.
• The structure of the option grant, including the vesting schedule over several years, is typical for executive compensation packages aimed at long-term retention and performance alignment.
• Specific comparable companies or projects are not detailed within this filing to assess the competitiveness of this particular grant relative to industry benchmarks.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for future dilution upon exercise of options, but also benefit from incentivized executive performance.
• Employees: The grant to a key executive may signal stability and a commitment to retaining top talent.
• Management: The Chief Business Officer receives a significant equity incentive, tying personal wealth creation to company performance.

Next Steps

• The options will begin vesting on January 6, 2027, with subsequent monthly vesting through January 6, 2030.
• The Chief Business Officer will continue to provide service to the company to ensure vesting of the options.

Key Dates

Keywords

Climb Bio, CLYM, Stock Options, Executive Compensation, Form 4, Insider Trading, Perrin Megan Wilson, Chief Business Officer, Equity Grant